MX2021008131A - Metodos y composiciones para el tratamiento de la enfermedad de fabry. - Google Patents
Metodos y composiciones para el tratamiento de la enfermedad de fabry.Info
- Publication number
- MX2021008131A MX2021008131A MX2021008131A MX2021008131A MX2021008131A MX 2021008131 A MX2021008131 A MX 2021008131A MX 2021008131 A MX2021008131 A MX 2021008131A MX 2021008131 A MX2021008131 A MX 2021008131A MX 2021008131 A MX2021008131 A MX 2021008131A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- fabry
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788439P | 2019-01-04 | 2019-01-04 | |
| PCT/US2020/012274 WO2020142752A1 (en) | 2019-01-04 | 2020-01-03 | Methods and compositions for the treatment of fabry disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008131A true MX2021008131A (es) | 2021-10-13 |
Family
ID=71407140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008131A MX2021008131A (es) | 2019-01-04 | 2020-01-03 | Metodos y composiciones para el tratamiento de la enfermedad de fabry. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200239911A1 (https=) |
| EP (1) | EP3906043A4 (https=) |
| JP (2) | JP7716338B2 (https=) |
| KR (1) | KR20210112337A (https=) |
| CN (1) | CN113423419A (https=) |
| AU (1) | AU2020204718B2 (https=) |
| BR (1) | BR112021012249A2 (https=) |
| CA (1) | CA3124564A1 (https=) |
| IL (1) | IL284414A (https=) |
| MX (1) | MX2021008131A (https=) |
| SG (1) | SG11202107325TA (https=) |
| WO (1) | WO2020142752A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102712926B1 (ko) * | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| US20220298514A1 (en) * | 2019-09-11 | 2022-09-22 | Aav Gene Therapeutics, Inc. | Aav-zyme and use for infusion replacement therapy |
| CA3183951A1 (en) * | 2020-07-14 | 2022-01-20 | Birgitte Rono | Apc targeting units for immunotherapy |
| AU2021356684A1 (en) * | 2020-10-09 | 2023-05-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AR124981A1 (es) * | 2021-02-26 | 2023-05-24 | Takeda Pharmaceuticals Co | Composición y métodos para el tratamiento de la enfermedad de fabry |
| CA3229998A1 (en) * | 2021-08-25 | 2023-03-02 | Canbridge Pharmaceuticals, Inc. | Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease |
| EP4426846A4 (en) * | 2021-11-03 | 2025-11-05 | Sangamo Therapeutics Inc | METHODS OF USING VIRAL VECTOR CONSTRUCTIONS FOR THE TREATMENT OF FABRY DISEASE |
| US20240408157A1 (en) * | 2021-12-02 | 2024-12-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| CN118475373A (zh) * | 2021-12-31 | 2024-08-09 | 九天生物医药(上海)有限公司 | 用于法布雷病的基因治疗的重组aav |
| CN119095612A (zh) * | 2022-02-25 | 2024-12-06 | 阿斯克肋匹奥生物制药公司 | 用于在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒 |
| CN117551636B (zh) * | 2023-04-30 | 2024-11-08 | 四川至善唯新生物科技有限公司 | 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271614B2 (en) * | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
| KR100545945B1 (ko) * | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| GB0024550D0 (https=) * | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| US8865881B2 (en) * | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| JPWO2012147370A1 (ja) * | 2011-04-28 | 2014-07-28 | 国立大学法人山口大学 | ターミネータ配列を含む高発現用リバースプライマー及びリニアｄｎａ |
| EP3285788B1 (en) * | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| MX390848B (es) * | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
| CN105950664B (zh) * | 2016-05-17 | 2019-03-29 | 上海优卡迪生物医药科技有限公司 | 一种靶向cd123的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 |
| WO2017201328A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
| KR102712926B1 (ko) * | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| JOP20190200A1 (ar) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| CA3089587A1 (en) * | 2018-02-08 | 2019-08-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
-
2020
- 2020-01-03 CN CN202080010090.6A patent/CN113423419A/zh active Pending
- 2020-01-03 WO PCT/US2020/012274 patent/WO2020142752A1/en not_active Ceased
- 2020-01-03 JP JP2021538993A patent/JP7716338B2/ja active Active
- 2020-01-03 CA CA3124564A patent/CA3124564A1/en active Pending
- 2020-01-03 MX MX2021008131A patent/MX2021008131A/es unknown
- 2020-01-03 US US16/734,271 patent/US20200239911A1/en active Pending
- 2020-01-03 KR KR1020217023276A patent/KR20210112337A/ko active Pending
- 2020-01-03 EP EP20735863.1A patent/EP3906043A4/en active Pending
- 2020-01-03 SG SG11202107325TA patent/SG11202107325TA/en unknown
- 2020-01-03 BR BR112021012249-4A patent/BR112021012249A2/pt unknown
- 2020-01-03 AU AU2020204718A patent/AU2020204718B2/en active Active
-
2021
- 2021-06-27 IL IL284414A patent/IL284414A/en unknown
-
2025
- 2025-07-18 JP JP2025121650A patent/JP2025142225A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3906043A4 (en) | 2022-10-26 |
| US20200239911A1 (en) | 2020-07-30 |
| AU2020204718A1 (en) | 2021-07-08 |
| CA3124564A1 (en) | 2020-07-09 |
| SG11202107325TA (en) | 2021-08-30 |
| JP2022516317A (ja) | 2022-02-25 |
| WO2020142752A1 (en) | 2020-07-09 |
| AU2020204718B2 (en) | 2026-02-12 |
| KR20210112337A (ko) | 2021-09-14 |
| CN113423419A (zh) | 2021-09-21 |
| JP2025142225A (ja) | 2025-09-30 |
| JP7716338B2 (ja) | 2025-07-31 |
| IL284414A (en) | 2021-08-31 |
| EP3906043A1 (en) | 2021-11-10 |
| BR112021012249A2 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008131A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
| CR20210489A (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento | |
| ECSP10010372A (es) | Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| UY31073A1 (es) | Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap) | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| MX348464B (es) | Agente inductor de inmunidad. | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| MX2021011958A (es) | Terapias genicas para trastornos lisosomales. | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| PE20260442A1 (es) | Composiciones y metodos para tratar la enfermedad celiaca | |
| UY38068A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX2020009532A (es) | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CL2020002561A1 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| AR106538A1 (es) | Métodos y composiciones para el tratamiento de la amiloidosis |